{"name":"ProQR Therapeutics","slug":"proqr-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"QR-010","genericName":"QR-010","slug":"qr-010","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"QR-010","genericName":"QR-010","slug":"qr-010","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNT1d1VDVrVUFBUXVnS1RBSjRfZnB2OUxXMnJneC11XzlhV3g5WkE5UUUzUVlnYVFJQ05VdXpEdU9oWkJzNU1CTnlJa2N2dnNDRkw4UkxFam9TZWgwem5YSkdQNXBsMUszYjZCZTZjSjJMZGYyZkN1RUM2RENQbUdadldLWEZiZnFLYTd2NG1XR2V1NXBkNWtKUDFGWGJsTnNSUDNrSExzbWF3Z2dTT1VyUDRmOWRDRFl2cWxjZDh6UGJzZGVUMHI4RmJpM1dackhFVkJ3VFppNkFjT3VLNUwtZ1pjMXFDVGRmZzQzYkdXdl83SjlhTnVsM0x0cjMtdE04VXJBNVdxc09aSXZNWk02OGdidGp5SGE5VjdZNWVmRXFLdXJzN0hmY1Y0VnZPemVnOXVrZHRpbmFpNW5SR2JlT3ZMQ1hfcWNDcU9z?oc=5","date":"2026-04-03","type":"regulatory","source":"Barchart.com","summary":"Obesity Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Merck, Alizyme, Bayer, GlaxoSmithKline, Bristol-Myers Squibb, Currax Pharma, Roche - Ba","headline":"Obesity Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Merck, ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNZFhobEYyVlpka3FaNFRGSUNBOGJUUnVmS245NW9PYXN1aWlKY01jUVdqZUN3UW1PMDVEbktQcDZORVktYktUcVpwRnhzb1dzLURvRlpUSjQ0RnF0bmIzZ0doMUNTYndTVkVaSE45ZFlMeTZKblYxdnBtaUc1VTVPbVkxSkI1c29LRzFVcGEtVjhHNmJOWkJZaXc3QnpnVGZKX29VSmppZEVtZF9wMkZrdDNINy0?oc=5","date":"2026-03-09","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Monday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPTVc0QW42c0ZPZzR0YmtkcXBfb2oyYkJCQmkwQXd6ODJfVWVBQkU4ODUyaEFldkpGRDJvRmdiY3pobnV6WkpyVTBzTzI0YUxvclQyc1dERWRvZkRwYm1CYks5RnBwTi1nUktWT0JTdm10cV80VXQyVkdsbTFXQXVQTlpzV2dmeUppcVdabE9ZWlJ4Y19faVlTZnQ1bm5DcU9GeGwyaWJQOXUwU1JHT0VmZkxrTE44eG5ZNFFvTjA0VzJETmgxRkNlRkpEcHBGV3VvdnVwZlNkVHFWQWp3a25KM1JLQ1JQMm_SAewBQVVfeXFMTUxvNVRYZFI4aGhzbVhHV2tYV2ZWZXREWEl2WE5oR3UwSmdzU2p1MUJqVFc5dWwtU3dKdi1DZ21wOXUwdW5TWVBJanp1czk5ZVZyNVVJSUlXSGZZZkxOdXNmS3Y3NkJ0azFQSV9Od3pYdlJwWldTZHdLUFNnamRZWWNkb0I2dlpLOXhsODlsSXZueTBQdnF6NTZLakFZVkRuU2VyTzF3bEc4Ykg5b29PeVpRN0JVOHlubkx6eVFXdHF2VEpDMGRtbWdLM01PYW9FOV9EV0JxcHVPbldPOGJzWlZ0Ym1SUGgwS1RMVVM?oc=5","date":"2026-01-13","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPd1hLVnJDZV9wVVczQjhJRnpIeFEyOE4tb1JWUGdRNWllMFdELThrc0RiVzNmSm1JS014Ui10SS1CYzJQT3lhVUZxem5SOXVQWFpacndScXY2V2tveFRRVjEyX3VrY3RQOTN3UDE4VXhKU21rMnhMV2VCRU82TnV5VnFnekswelgwQ2puX1Fhdks3SDdaTmdSRmtqQ2ttMjZSRllmTmNlbU5iQQ?oc=5","date":"2025-12-04","type":"pipeline","source":"PMLiVE","summary":"TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board - PMLiVE","headline":"TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1MbGNmTEJyWEJvWlg4SlQ4M3MzQi1URVlwbGdTRS1yZ201QXlfb3A3WnlEa3pUTzNRLXRlaFlMdy1KVUJURVpnTXJTUDBjbm4xSlR2Ug?oc=5","date":"2025-12-03","type":"pipeline","source":"Pharmafile","summary":"Faron Pharmaceuticals appoints Jurriaan Dekkers as Chief Financial Officer - Pharmafile","headline":"Faron Pharmaceuticals appoints Jurriaan Dekkers as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOX0Z0Rk5HMkxiUFE2SDU4MVlvVENsSHpDSFhXekl4VVFjSGNBeXBjbl8zVUhFb1YySE9WdnlrbV8zdHVaNFBCOVIzR2R1aGhBdTRvQldqWUF2ODhLN0hXTjJVMU8zOExuZmxORGt6U2FUdlg1c1JRR2sxMFBVa1FaQndsQnFZWWFNUU9kZ2Y3dzMzSXVqOTBkYjdUcVhxU25V?oc=5","date":"2025-11-10","type":"pipeline","source":"Fierce Biotech","summary":"Eli Lilly pens $1.2B pact with Sanegene to better target metabolic RNA meds - Fierce Biotech","headline":"Eli Lilly pens $1.2B pact with Sanegene to better target metabolic RNA meds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPN202TUJ4Nm1xZ3AwUEFZbjh0cGl1NWc5WDJFLW03VHhlZnV0R28wOFR4UC0wNlJnSHV6WVY4aG9mdEtDZ1phbHdKWnUyaEhuTzUteERfdkpJdnA1S1VZVGp3TlpwcXhxeEJZeEttTzYwZlNKTHBtZ0dXVGhtSnZZeUs3bkxhTFpVZ2d0c3d5Mm83eGtlRmZJU3FseW5lYVhoeVBESV8zRW9fb1FPTk1jd1ZUb1dyeGlrTFBuMUhCcFBzTnI2azJadG9fWHlxVS1RX0Roc3NNbnIwS19aVEJXbE5zQUJBUHVwdDhhYlluVGZhcXlRVW1wak5xazJ2bFlNMmFzaV9oVENvOWRsTEJFdVRwc2Z3TURveTlIRkJRQXpLV3JWTldMRnBwZG1EdEJSVGdTVlhUVktvS3drSHFrTGFZUmhpcnpOUXl2cEN5OERFZVpE?oc=5","date":"2025-06-17","type":"trial","source":"GlobeNewswire","summary":"Oligonucleotides Clinical Trial Pipeline Analysis - GlobeNewswire","headline":"Oligonucleotides Clinical Trial Pipeline Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNaDVVdTJkT0hqOU1ubkRWaW5qM29UVjVMRGpVdUUyMWEzN0hOaXRhUk1PcDJTNTRUcThCYTRuRFNXbk9HRkszQ1lBUXRMR2gxUUl0OUxmLUxoOG5xbG4wMHZvaG1TaWlXQjQ2SENlbWRkdDVGUzRpY09pZVBRNnl5ODhQZHVnVWxfcl9GNkFtbXkyaENBZTJiSg?oc=5","date":"2023-09-27","type":"pipeline","source":"BioPharma Dive","summary":"ProQR sale of eye drugs comes undone over employment contracts - BioPharma Dive","headline":"ProQR sale of eye drugs comes undone over employment contracts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQckp4c3dOQVE4NTcxV3p5elpxT01kZ3BRZlYzMEZhUU9nejZNaV9nTVNuOEFnd3pOZ1J6eGh1bUhoZ1FwdDNmMTBSWlRGVWkzaTVwWTF3cTdTekZHekpkeGN0SXhLZjNpaTRvMWRHWjcwcFZXbmpqU3d3ZWxjU0xIYlIyc0NMQzRhLUtEZW9LUXRmb0hO?oc=5","date":"2022-12-22","type":"deal","source":"BioPharma Dive","summary":"Lilly pays $75M to widen RNA editing deal with ProQR - BioPharma Dive","headline":"Lilly pays $75M to widen RNA editing deal with ProQR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQdXVLVWlvUlhCWmV1UTlmOXduNWlrZHNWQ092aTRWZ2h1aGYxZVNMTHdsOGs3Q1ZXQXlKVEtRVENZaW5VSV8tcXFhZlhLVnVuUWhrTGxYZ1l0WkJCRUxfc0o5NjBCQ1M0UDJrSkxyN1BkM0JnWGJyaHJCSVhMbC16d2UyTGhyd1g0WHVnSmh2R0JuVEly?oc=5","date":"2021-10-23","type":"deal","source":"C&EN","summary":"RNA-editing race intensifies as Big Pharma buys in - C&EN","headline":"RNA-editing race intensifies as Big Pharma buys in - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdTFWQjliSXJpbmJBSktLSE5OWjZ2R3lXTVVBYVh2Qy0tUURqNzJuSXRBMEpOUWE5R0duVGhjTEtzUk9WWXdKcDV4QzN2ME5WZkUzTzhUbEpXeko3dkVxNlhISlBWNTZrZGlkT3hpNnlxTFFWaXBnMFVIcHNLcW5UWnFjdGt4YjJJdVhEMENDakxCTjJ3V3FaNk5udGRkV0tXeTB0aWVlTmxLb2s?oc=5","date":"2021-04-22","type":"pipeline","source":"drugdiscoverytrends.com","summary":"How ProQR aims to use RNA therapy to target genetic forms of blindness - drugdiscoverytrends.com","headline":"How ProQR aims to use RNA therapy to target genetic forms of blindness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1TRUg3RmhPWmJuRWZ2cDFac1BROExtaEV3ZFNkd0J0NUwwVVVGNDhWTHM4VlRzMDFjVUJ6aU9BX09KUllhZ1ZxREFYZGoxRnE2SlNmNXpEYzRwRlFMenBFTUhMVVNUd2tzb3pQWWN2Zm5PeFJZ?oc=5","date":"2019-01-02","type":"regulatory","source":"Contract Pharma","summary":"FDA Grants ProQR FTD - Contract Pharma","headline":"FDA Grants ProQR FTD","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}